S&P 500   3,376.04 (+0.08%)
DOW   27,943.75 (+0.17%)
QQQ   271.70 (-0.29%)
AAPL   455.41 (-1.01%)
MSFT   208.37 (-0.16%)
FB   259.83 (-0.56%)
GOOGL   1,507.48 (-0.60%)
AMZN   3,147.73 (-0.42%)
NVDA   460.29 (+0.56%)
CGC   17.18 (-0.81%)
BABA   252.56 (-0.46%)
TSLA   1,647.40 (+1.63%)
GE   6.68 (+1.21%)
MU   45.74 (-0.87%)
AMD   81.30 (-0.66%)
T   30.13 (+0.74%)
F   7.09 (+0.85%)
ACB   10.58 (+3.93%)
GILD   68.43 (+0.37%)
NFLX   482.61 (+0.27%)
DIS   130.70 (-0.20%)
BAC   26.52 (+0.65%)
BA   178.15 (+1.96%)
S&P 500   3,376.04 (+0.08%)
DOW   27,943.75 (+0.17%)
QQQ   271.70 (-0.29%)
AAPL   455.41 (-1.01%)
MSFT   208.37 (-0.16%)
FB   259.83 (-0.56%)
GOOGL   1,507.48 (-0.60%)
AMZN   3,147.73 (-0.42%)
NVDA   460.29 (+0.56%)
CGC   17.18 (-0.81%)
BABA   252.56 (-0.46%)
TSLA   1,647.40 (+1.63%)
GE   6.68 (+1.21%)
MU   45.74 (-0.87%)
AMD   81.30 (-0.66%)
T   30.13 (+0.74%)
F   7.09 (+0.85%)
ACB   10.58 (+3.93%)
GILD   68.43 (+0.37%)
NFLX   482.61 (+0.27%)
DIS   130.70 (-0.20%)
BAC   26.52 (+0.65%)
BA   178.15 (+1.96%)
S&P 500   3,376.04 (+0.08%)
DOW   27,943.75 (+0.17%)
QQQ   271.70 (-0.29%)
AAPL   455.41 (-1.01%)
MSFT   208.37 (-0.16%)
FB   259.83 (-0.56%)
GOOGL   1,507.48 (-0.60%)
AMZN   3,147.73 (-0.42%)
NVDA   460.29 (+0.56%)
CGC   17.18 (-0.81%)
BABA   252.56 (-0.46%)
TSLA   1,647.40 (+1.63%)
GE   6.68 (+1.21%)
MU   45.74 (-0.87%)
AMD   81.30 (-0.66%)
T   30.13 (+0.74%)
F   7.09 (+0.85%)
ACB   10.58 (+3.93%)
GILD   68.43 (+0.37%)
NFLX   482.61 (+0.27%)
DIS   130.70 (-0.20%)
BAC   26.52 (+0.65%)
BA   178.15 (+1.96%)
S&P 500   3,376.04 (+0.08%)
DOW   27,943.75 (+0.17%)
QQQ   271.70 (-0.29%)
AAPL   455.41 (-1.01%)
MSFT   208.37 (-0.16%)
FB   259.83 (-0.56%)
GOOGL   1,507.48 (-0.60%)
AMZN   3,147.73 (-0.42%)
NVDA   460.29 (+0.56%)
CGC   17.18 (-0.81%)
BABA   252.56 (-0.46%)
TSLA   1,647.40 (+1.63%)
GE   6.68 (+1.21%)
MU   45.74 (-0.87%)
AMD   81.30 (-0.66%)
T   30.13 (+0.74%)
F   7.09 (+0.85%)
ACB   10.58 (+3.93%)
GILD   68.43 (+0.37%)
NFLX   482.61 (+0.27%)
DIS   130.70 (-0.20%)
BAC   26.52 (+0.65%)
BA   178.15 (+1.96%)
Log in

NASDAQ:NUVANuVasive Stock Price, Forecast & News

$51.95
+0.27 (+0.52 %)
(As of 08/14/2020 12:12 PM ET)
Add
Compare
Today's Range
$51.17
Now: $51.95
$52.13
50-Day Range
$51.17
MA: $56.07
$60.75
52-Week Range
$28.55
Now: $51.95
$81.91
Volume3,568 shs
Average Volume957,356 shs
Market Capitalization$2.66 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.36
NuVasive, Inc., a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons to access the spine to perform restorative and fusion procedures in a minimally-disruptive fashion. The company's biologics products include Osteocel Plus and Pro, a cellular bone matrix; Formagraft, a collagen-based synthetic bone substitute; AttraX, a synthetic bone graft material; and Propel DBM, a moldable demineralized bone matrix putty and gel. Its IOM services are used for onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company also provides implants used for interbody disc height restoration; and fixation products, including pedicle screws, rods, and plates. In addition, it offers Integrated Global Alignment platform for assessing, preserving, and restoring spinal alignment; MAGEC-early onset scoliosis, a spinal bracing and distraction system; and PRECICE, a limb lengthening system. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly-employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was founded in 1997 and is headquartered in San Diego, California.
Read More
NuVasive logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.77 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:NUVA
CUSIP67070410
Phone858-909-1800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.17 billion
Cash Flow$5.33 per share
Book Value$17.58 per share

Profitability

Net Income$65.23 million

Miscellaneous

Employees2,800
Market Cap$2.66 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$51.95
+0.27 (+0.52 %)
(As of 08/14/2020 12:12 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NUVA News and Ratings via Email

Sign-up to receive the latest news and ratings for NUVA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











NuVasive (NASDAQ:NUVA) Frequently Asked Questions

How has NuVasive's stock price been impacted by COVID-19 (Coronavirus)?

NuVasive's stock was trading at $49.41 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NUVA shares have increased by 5.1% and is now trading at $51.95.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of NuVasive?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 1 sell rating, 6 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for NuVasive
.

When is NuVasive's next earnings date?

NuVasive is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for NuVasive
.

How were NuVasive's earnings last quarter?

NuVasive, Inc. (NASDAQ:NUVA) issued its earnings results on Tuesday, August, 4th. The medical device company reported ($0.40) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.47) by $0.07. The medical device company had revenue of $203.61 million for the quarter, compared to analyst estimates of $203.67 million. NuVasive had a negative net margin of 0.36% and a positive return on equity of 8.33%. The company's quarterly revenue was down 30.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.63 earnings per share.
View NuVasive's earnings history
.

What guidance has NuVasive issued on next quarter's earnings?

NuVasive updated its second quarter 2020 After-Hours earnings guidance on Monday, July, 20th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $202-205 million, compared to the consensus revenue estimate of $151.58 million.

What price target have analysts set for NUVA?

16 analysts have issued twelve-month target prices for NuVasive's stock. Their forecasts range from $55.00 to $93.00. On average, they expect NuVasive's stock price to reach $71.31 in the next year. This suggests a possible upside of 37.3% from the stock's current price.
View analysts' price targets for NuVasive
.

Has NuVasive been receiving favorable news coverage?

News stories about NUVA stock have been trending somewhat negative on Friday, according to InfoTrie. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. NuVasive earned a media sentiment score of -1.6 on InfoTrie's scale. They also assigned news headlines about the medical device company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near future.
View the latest news about NuVasive
.

Who are some of NuVasive's key competitors?

What other stocks do shareholders of NuVasive own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include Incyte (INCY), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), Medivation (MDVN), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Starbucks (SBUX), First Solar (FSLR) and Global Sources Ltd. (Bermuda) (GSOL).

Who are NuVasive's key executives?

NuVasive's management team includes the following people:
  • Mr. J. Christopher Barry, CEO & Director (Age 46)
  • Mr. Matthew W. Link, Pres (Age 44)
  • Dr. Peter M. Leddy, Exec. VP of People & Culture (Age 56)
  • Mr. Rajesh J. Asarpota, Exec. VP & CFO (Age 52)
  • Mr. Jereme Sylvain, Chief Accounting Officer (Age 39)

What is NuVasive's stock symbol?

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

Who are NuVasive's major shareholders?

NuVasive's stock is owned by many different retail and institutional investors. Top institutional shareholders include Copper Rock Capital Partners LLC (19.16%), Vanguard Group Inc. (9.87%), Anchor Capital Advisors LLC (2.34%), Macquarie Group Ltd. (2.03%), Fisher Asset Management LLC (1.91%) and Victory Capital Management Inc. (1.48%). Company insiders that own NuVasive stock include Gregory T Lucier, Matthew Link and Paul Mcclintock.
View institutional ownership trends for NuVasive
.

Which major investors are selling NuVasive stock?

NUVA stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Federated Hermes Inc., Vanguard Group Inc., SG Americas Securities LLC, Prudential Financial Inc., Ziegler Capital Management LLC, Anchor Capital Advisors LLC, and Fisher Asset Management LLC. Company insiders that have sold NuVasive company stock in the last year include Gregory T Lucier, Matthew Link, and Paul Mcclintock.
View insider buying and selling activity for NuVasive
.

Which major investors are buying NuVasive stock?

NUVA stock was bought by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, Scout Investments Inc., Kornitzer Capital Management Inc. KS, Healthcare of Ontario Pension Plan Trust Fund, Macquarie Group Ltd., Bellevue Group AG, Dana Investment Advisors Inc., and Victory Capital Management Inc..
View insider buying and selling activity for NuVasive
.

How do I buy shares of NuVasive?

Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NuVasive's stock price today?

One share of NUVA stock can currently be purchased for approximately $51.95.

How big of a company is NuVasive?

NuVasive has a market capitalization of $2.66 billion and generates $1.17 billion in revenue each year. The medical device company earns $65.23 million in net income (profit) each year or $2.47 on an earnings per share basis. NuVasive employs 2,800 workers across the globe.

What is NuVasive's official website?

The official website for NuVasive is www.nuvasive.com.

How can I contact NuVasive?

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-909-1800 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.